SINOMED(SH:688108) Sou Hu Cai Jing·2025-07-27 20:38Core Viewpoint - Sino Medical (688108) reported a significant increase in revenue and net profit for the first half of 2025, indicating strong business performance driven by product sales growth [2][4]. Group 1: Trading Information - As of July 25, 2025, Sino Medical's stock closed at 12.92 yuan, up 3.36%, with a turnover rate of 6.34% and a trading volume of 263,800 shares, amounting to a transaction value of 348 million yuan [1]. - On the same day, the fund flow showed a net outflow of 6.6266 million yuan from institutional investors, 11.7621 million yuan from speculative funds, and a net inflow of 18.3887 million yuan from retail investors [2][4]. Group 2: Company Announcements - Sino Medical announced a half-year performance forecast for 2025, estimating revenue of 240.48 million yuan, a year-on-year increase of 12.53%, and a net profit attributable to shareholders of 13.84 million yuan, a year-on-year increase of 296.54% [2][4]. - The net profit after deducting non-recurring gains and losses is projected to be 7.98 million yuan, reflecting a year-on-year growth of 163.35% [2][3]. Group 3: Reasons for Performance Growth - The growth in performance is attributed to a significant increase in sales of two coronary stent products and coronary balloon products, stable growth in neurointerventional business, a slight increase in operating costs, and a decrease in sales and R&D expenses [3]. - Management expenses increased year-on-year, while investment income and asset impairment losses decreased [3].